Close Menu

NEW YORK – Bruker on Tuesday reported that its fourth quarter revenues were up 5 percent year over year.

For the three months ended Dec. 31, the company reported revenues of $627.5 million, up from $599.9 million in Q4 2019, and beating the consensus Wall Street estimate of $602.0 million.

Organic revenue growth during the quarter was down a fraction of a percent, as acquisitions added a fraction of a percent while foreign currency translation had a positive effect of 5 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.